BR112021011858A2 - Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite b - Google Patents
Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite bInfo
- Publication number
- BR112021011858A2 BR112021011858A2 BR112021011858A BR112021011858A BR112021011858A2 BR 112021011858 A2 BR112021011858 A2 BR 112021011858A2 BR 112021011858 A BR112021011858 A BR 112021011858A BR 112021011858 A BR112021011858 A BR 112021011858A BR 112021011858 A2 BR112021011858 A2 BR 112021011858A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- heteroaryldihydropyrimidine
- infections
- derivatives
- treating hepatitis
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
derivados de heteroarildihidropirimidina e métodos de tratamento de infecções de hepatite b. a presente invenção refere-se a compostos úteis para o tratamento de infecção pelo vhb em um sujeito em necessidade dos mesmos, composições farmacêuticas dos mesmos e métodos de inibição, supressão ou prevenção de infecção pelo vhb no sujeito.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018122258 | 2018-12-20 | ||
US201962791576P | 2019-01-11 | 2019-01-11 | |
PCT/CN2019/126739 WO2020125730A1 (en) | 2018-12-20 | 2019-12-19 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021011858A2 true BR112021011858A2 (pt) | 2021-11-30 |
Family
ID=71102522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021011858A BR112021011858A2 (pt) | 2018-12-20 | 2019-12-19 | Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite b |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230165865A1 (pt) |
EP (1) | EP3898632A4 (pt) |
JP (1) | JP2022513297A (pt) |
KR (1) | KR20210106464A (pt) |
CN (1) | CN113195499A (pt) |
AU (1) | AU2019410640A1 (pt) |
BR (1) | BR112021011858A2 (pt) |
CA (1) | CA3118764A1 (pt) |
IL (1) | IL284116A (pt) |
MA (1) | MA54556A (pt) |
MX (1) | MX2021007602A (pt) |
SG (1) | SG11202105338VA (pt) |
TW (1) | TW202035412A (pt) |
WO (1) | WO2020125730A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11639350B2 (en) | 2017-06-27 | 2023-05-02 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
JP2022511819A (ja) * | 2018-12-20 | 2022-02-01 | ヤンセン ファーマシューティカ エヌ.ベー. | ヘテロアリールジヒドロピリミジン誘導体及びb型肝炎感染症を治療する方法 |
CN111825676B (zh) * | 2019-04-15 | 2023-10-17 | 广东东阳光药业股份有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
WO2020255016A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
CA3140702A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
TW202246269A (zh) | 2021-01-29 | 2022-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 二氫嘧啶衍生物及其用於治療hbv感染或hbv誘發的疾病之用途 |
CN114907355A (zh) * | 2021-02-09 | 2022-08-16 | 上海维申医药有限公司 | 一种二氢嘧啶类化合物、其制备方法及其应用 |
WO2022257942A1 (en) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015004113A2 (pt) * | 2012-09-10 | 2017-07-04 | Hoffmann La Roche | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
BR112015028873A2 (pt) * | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
PL3114128T3 (pl) * | 2014-03-07 | 2019-06-28 | F. Hoffmann-La Roche Ag | Nowe skondensowane w pozycji 6 heteroarylodihydropirymidyny stosowane w leczeniu i profilaktyce zakażenia wirusem zapalenia wątroby typu B |
KR20160133563A (ko) * | 2014-03-28 | 2016-11-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 |
KR102139708B1 (ko) * | 2015-03-16 | 2020-07-31 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제를 사용하는 병용 치료 |
WO2017064156A1 (en) * | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
AR107633A1 (es) * | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
-
2019
- 2019-12-18 TW TW108146369A patent/TW202035412A/zh unknown
- 2019-12-19 KR KR1020217020628A patent/KR20210106464A/ko not_active Application Discontinuation
- 2019-12-19 CN CN201980084849.2A patent/CN113195499A/zh active Pending
- 2019-12-19 WO PCT/CN2019/126739 patent/WO2020125730A1/en unknown
- 2019-12-19 US US17/415,712 patent/US20230165865A1/en active Pending
- 2019-12-19 CA CA3118764A patent/CA3118764A1/en active Pending
- 2019-12-19 SG SG11202105338VA patent/SG11202105338VA/en unknown
- 2019-12-19 AU AU2019410640A patent/AU2019410640A1/en not_active Abandoned
- 2019-12-19 BR BR112021011858A patent/BR112021011858A2/pt unknown
- 2019-12-19 MA MA054556A patent/MA54556A/fr unknown
- 2019-12-19 JP JP2021534914A patent/JP2022513297A/ja not_active Withdrawn
- 2019-12-19 MX MX2021007602A patent/MX2021007602A/es unknown
- 2019-12-19 EP EP19897899.1A patent/EP3898632A4/en not_active Withdrawn
-
2021
- 2021-06-17 IL IL284116A patent/IL284116A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022513297A (ja) | 2022-02-07 |
MX2021007602A (es) | 2021-08-11 |
CN113195499A (zh) | 2021-07-30 |
EP3898632A1 (en) | 2021-10-27 |
CA3118764A1 (en) | 2020-06-25 |
EP3898632A4 (en) | 2023-02-22 |
TW202035412A (zh) | 2020-10-01 |
MA54556A (fr) | 2021-10-27 |
SG11202105338VA (en) | 2021-07-29 |
IL284116A (en) | 2021-08-31 |
US20230165865A1 (en) | 2023-06-01 |
AU2019410640A1 (en) | 2021-05-27 |
KR20210106464A (ko) | 2021-08-30 |
WO2020125730A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021011858A2 (pt) | Derivados de heteroarildi-hidropirimidina e métodos de tratamento de infecções de hepatite b | |
EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
EA201691440A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
EA202091114A1 (ru) | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) | |
BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
MX2020004839A (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
PH12018502058A1 (en) | Thiazolide compounds for treating viral infections | |
BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
MX2018002707A (es) | Derivados de tetrahidrofurano antivirales. | |
BR112018073858A2 (pt) | métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 | |
WO2017161133A8 (en) | N-hydroxyisoquinolinedione inhibitors of hbv replication | |
BR112019023130A2 (pt) | Compostos e métodos para tratamento de infecções bacterianas | |
CU20210089A7 (es) | Compuestos derivados de fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) |